• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS Live: First in-human results for the OmniVu IOL system

Video

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

George Waring IV, MD:

Hi, it's George Waring from the Waring Vision Institute in Mount Pleasant, South Carolina, and I'm here at the American Society of Cataract and Refractive Surgery in San Diego where I had the distinct honor of presenting the first in-human results for the OmniVu IOL system.


The OmniVu IOL system is a modular shape-changing IOL by Atia Vision designed to provide a full range of functional vision while preserving visual quality. The IOL system was designed with other accommodative technologies, historical technologies, and all the learning lessons that we've gathered over the years. So the results were as follows: 20/32 visual acuity over 2.75 diopters of defocus monocularly and then extended out to 4 diopters when measured binocularly. One hunded percent of patients achieved 20/20 or greater distance corrected visual acuity and intermediate visual acuity and 20/32 or better near visual acuity.


We couldn't be more excited about this. The results were stable over 6 months. and I think this is just really promising technology for what may represent a new chapter in presbyopia correction and presbyopia IOLs. Thank you very much.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.